An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
← catalyst calendarNCT07573631 · readout ≤ 1,960 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18estimated
Sites
6
Countries
Italy, Netherlands, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-20 | actual | When the study began enrolling |
| Primary completion | Dec 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy (DMD)
Intervention
- Drug: BMN 351
Primary outcome
what the primary-completion date above is the date OFTo assess the long-term safety and tolerability of BMN 351 in participants with DMD
measured Through study completion, at least 1 year
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed